Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

tigator, Thomas J. Louie, M.D., presented top-line data from Optimer's fidaxomicin North American Phase 3 clinical study for patients with Clostridium difficile infection at the European Congress of Clinical Microbiology and Infectious Diseases meeting, which showed the trial met its primary endpoint of achieving clinical cure compared to Vancocin(R). In addition, the top-line data showed that patients treated with fidaxomicin experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a higher global cure (cure with no recurrence within four weeks) compared to Vancocin (p=0.006).
  • Clinical investigator, Mark A. Miller, M.D., presented additional data from Optimer's fidaxomicin North American Phase 3 clinical study at the Digestive Disease Week 2009 Conference focusing on patient risk factors believed to be predictive of CDI recurrence following treatment. These risk factors include albumin levels, white blood cell (WBC) count and temperature and strain types of CDI. The data showed that fidaxomicin overall demonstrated a lower recurrence rate compared to Vancocin (p=0.004) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains.
  • The United States Patent and Trademark Office issued Optimer a production patent covering steps used in the manufacture of fidaxomicin.
  • About Optimer Pharmaceuticals

    Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed t
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
    6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
    7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
    8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
    9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
    10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
    11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual list ... as number 1,361 in growth for the three years through 2014. Being named to ... privately held organizations in the country. , “We are thrilled to make the ...
    (Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
    (Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
    (Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
    Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
    ... , Jason S. Wood, Varian, ... , Cytochrome P450s (CYPs) ... human body 1 . CYPs are part of the Phase I ... the metabolized drug enabling either easy elimination of the drug or ...
    ... Z. Yang and S. Sadjadi, Varian, Inc. , ... Amphetamine drugs are often abused and misused in ... and doping laboratories are frequently asked to analyze for the presence ... sample volumes can be collected non-invasively. These drugs generally remain detectable ...
    ... cells through the B cell receptor or T cells through the ... different members of the same kinase families are used. ZAP-70 and ... and structures. Crosslinking of the CD3 receptor complex leads to the ... 1,2 . These kinases phosphorylate ITAM regions on the receptor which ...
    Cached Biology Technology:Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 2Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method 3Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS 2Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS 3Research Tools for Analysis of ZAP-70 2Research Tools for Analysis of ZAP-70 3
    (Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
    (Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s touch ... 2015 that relate to sales of FPC1155 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... manufacturer in China and we are proud ... for Z1 , its first ...
    (Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
    Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
    ... have had an accelerated childhood compared to that of modern ... by researchers from Ohio State University and the University of ... tooth growth present in the Neanderthal fossils they examined was ... , And since the rate of tooth growth has ...
    ... testing methods helped public health officials control and limit ... A virus in 2003 related to the consumption of ... the October 15 issue of The Journal of Infectious ... study, Joseph J. Amon, PhD, MSPH, and colleagues at ...
    ... testing methods helped public health officials control and limit ... A virus in 2003 related to the consumption of ... the October 15 issue of The Journal of Infectious ... study, Joseph J. Amon, PhD, MSPH, and colleagues at ...
    Cached Biology News:Neanderthal teeth grew no faster than comparable modern humans' 2Neanderthal teeth grew no faster than comparable modern humans' 3Disrupting Cocaine-memories To Battle Addiction 2Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance 2
    ... rat tissue extracts (liver, kidney, spleen, and heart) ... extract. It was also tested with microsomal fractions ... A simple and reliable method for measuring NDPase ... of the inorganic phosphate released from NDP by ...
    Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
    ... through 63 ligand binding ... a broad therapeutic range. ... many non human tissue ... assays. Used to ...
    ... Receptor (PR) Competitor Assay Kits are ... progesterone receptor binding compounds using fluorescence ... a fusion of glutathione transferase to ... progesterone receptor [PR-LBD(GST)] and a proprietary, ...
    Biology Products: